Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: tony who wrote (28930)	6/23/1999 7:43:00 PM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

As David Robinson noted (in Dow Jones, PRNewswire, and Bloomberg), Targretin was "central" to LGND's earnings. LGND's strategy has been to gain approval in a small niche market, and then rely on off label use for significant revenue. Today's press release reported favorable Targretin data for severe of moderate psoriasis, and noted that Targretin was in advanced breast cancer trials and interim data would be available later this year. If the clinical data is anywhere near the animal data, then Targretin sales will skyrocket, if approved for CTCL due to off label usage.